EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

KLF5-SLC2A1 axis promotes intrahepatic cholangiocarcinoma progression via SPP1 + macrophage-mediated microenvironment remodeling

Hui Li, Ying Zhu, Zhixiang Hu, Changjing Huang, Zhouyu Ning, Zhiqiang Meng

Cellular Oncology · 2026-12 · 49 (6)

DOI: 10.1007/s13402-026-01275-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 19.08.2026. Verfasst von Hui Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Shanghai,…. Hauptthemen laut MEDLINE: Glucose Transporter Type 1, Cholangiocarcinoma, Tumor Microenvironment, Macrophages. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tumor metabolic reprogramming shapes the tumor microenvironment (TME) and modulates anti-tumor immunity, yet the interplay between metabolic adaptation and immune regulation in intrahepatic cholangiocarcinoma (ICC) remains unclear. We investigated the role of the glucose transporter GLUT1 (SLC2A1) as a potential immunometabolic regulator in ICC. METHODS: We integrated bulk and single-cell transcriptomics with multi-omics profiling, and performed in vitro and in vivo functional validation. Pharmacologic inhibition was achieved using the selective GLUT1 inhibitor BAY-876. Single-cell analyses and tumor cell-macrophage co-culture assays were used to characterize immune composition and macrophage polarization. Mechanistic studies probed signaling pathways linking glucose transport to cytokine release and macrophage activation. RESULTS: GLUT1 expression was increased in malignant cholangiocytes and associated with worse prognosis. Single-cell data revealed stage-dependent GLUT1 dynamics, peaking at intermediate tumor states and declining during late-stage metabolic shifts toward lipid and MYC-driven programs. BAY-876 suppressed tumor cell proliferation and reduced tumor burden in preclinical models. High GLUT1 abundance correlated with an immune-suppressed TME reduced overall immune infiltration and predominance of M2-like macrophages, whereas GLUT1 inhibition increased tumor cell release of TNFα, activated NF-κB signaling in macrophages, and promoted M1-like polarization. Mechanistically, GLUT1 blockade activated p53 signaling and enhanced ADAM17 maturation, facilitating proteolytic release of TNFα and thereby engaging a p53/ADAM17/TNFα/NF-κB axis that links glucose transport to macrophage phenotype. CONCLUSIONS: These data nominate GLUT1 as an immunometabolic regulator in ICC and provide a rationale to evaluate GLUT1-directed strategies, alone or combined with immune-modulatory agents, to overcome metabolic heterogeneity and remodel the TME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucose Transporter Type 1CholangiocarcinomaTumor MicroenvironmentMacrophagesDisease ProgressionBile Duct NeoplasmsHumansAnimalsCell Line, TumorSignal TransductionMetabolic ReprogrammingCell Proliferation

Stichwörter der Autor:innen

ADAM17BAY-876GLUT1ImmunometabolismIntrahepatic cholangiocarcinomaMacrophage polarization

Substanzen

Glucose Transporter Type 1SLC2A1 protein, human

Autor:innen und Institutionen

  • Department of Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Shanghai, 200032, China.
  • Department of Integrative Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.
  • Department of Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Shanghai, 200032, China. yuzhou3065@126.com.
  • Department of Integrative Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China. yuzhou3065@126.com.
  • Department of Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Shanghai, 200032, China. mengshca@fudan.edu.cn.
  • Department of Integrative Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China. mengshca@fudan.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, H., Zhu, Y., Hu, Z., Huang, C., Ning, Z., & Meng, Z. (2026). KLF5-SLC2A1 axis promotes intrahepatic cholangiocarcinoma progression via SPP1 + macrophage-mediated microenvironment remodeling. Cellular Oncology, 49(6). https://doi.org/10.1007/s13402-026-01275-6

Vancouver

Li H, Zhu Y, Hu Z, Huang C, Ning Z, Meng Z. KLF5-SLC2A1 axis promotes intrahepatic cholangiocarcinoma progression via SPP1 + macrophage-mediated microenvironment remodeling. Cellular Oncology. 2026;49(6). doi:10.1007/s13402-026-01275-6

BibTeX
@article{Li2026,
  author = {Li, Hui and Zhu, Ying and Hu, Zhixiang and Huang, Changjing and Ning, Zhouyu and Meng, Zhiqiang},
  title = {KLF5-SLC2A1 axis promotes intrahepatic cholangiocarcinoma progression via SPP1 + macrophage-mediated microenvironment remodeling},
  journal = {Cellular Oncology},
  year = {2026},
  volume = {49},
  number = {6},
  doi = {10.1007/s13402-026-01275-6}
}
Kostenlos starten →